Bristol-Myers Squibb   4Q Revenues: $4.3 billion (+1%) 4Q Loss: $129 million (earnings were $27 million 4Q14) FY Revenues: $16.6 billion (+4%) FY Earnings: $1.7 billion (-17%) Comments: U.S. revenues increased 9% to $2.3 billion in the quarter. Opdivo sales were $475 million, up from $5 million in 4Q15. Eliquis sales were $602 million compared to $281 in 4Q14. Orencia sales were $540 million, up 22%. Baraclude sales were $309 million in the quarter, down 9% in the quarter. Hepatiti...